April 27, 2017

MSF campaign seeks greater access to vaccine against pneumonia, the leading cause of child mortality

NEW YORK, April 27, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is bringing individual investors’ voices to Pfizer’s annual general meeting today in New Jersey to hold the pharmaceutical corporation accountable and demand it lowers the price of the pneumonia vaccine for all children in all developing countries.

One week ago, MSF launched Your Stock Your Voice, a groundbreaking online tool that empowers people who may hold Pfizer stock through their investments, including retirement funds, to demand change that could save lives. Through this platform, people can find out whether their investment package includes Pfizer shares, and, if so, provides options for people to take action and put pressure on the company to lower the price of its pneumonia vaccine. In just a few days, hundreds of people and investors have shared messages on social media to ask the company to reduce the price of the vaccine to $5 per child (for all three doses) in all developing countries.

Pneumonia is the leading cause of child mortality worldwide, killing nearly one million children every year. Pfizer and GlaxoSmithKline (GSK) are the only two manufacturers of the pneumonia vaccine, and have priced the vaccine out of reach for many developing countries. In fact, one third of the world’s countries have not been able to introduce the vaccine, largely due to its high price.

“With coaxing from Pfizer’s investors all over the US, we hope the company will finally commit at their shareholder meeting to give all children in all developing countries a shot at being protected against the world’s biggest childhood killer, pneumonia,” said Jason Cone, executive director of MSF-USA. “It’s unconscionable that there’s a lifesaving vaccine, but tens of millions of children across the globe are being deprived of it because Pfizer charges too high a price. We call on Pfizer to reduce the price to $5 for all three doses, for all children in all developing countries.”

MSF has tried to negotiate a lower price with Pfizer for years. After years of fruitless negotiations with both Pfizer and GSK for an affordable price, MSF launched in 2015 A Fair Shot, a public campaign calling on both pharmaceutical corporations to reduce the price of the pneumonia vaccine. Through the Fair Shot campaign, more than half a million people around the world mobilized to call on Pfizer and GSK to lower the price.

In November 2016, following a similar announcement made by GSK, Pfizer finally agreed to reduce the price for humanitarian organizations working in emergencies, such as MSF, to just over $9 per child (for all three doses). MSF and Pfizer are still negotiating a supply agreement that fulfills Pfizer’s public commitment. Pfizer should limit the number of conditions it is attempting to insert in the agreement so that MSF can have adequate supply of the pneumonia vaccine and the ability to protect as many children as possible.

While Pfizer’s commitment to humanitarian emergencies represents a step in the right direction, it is still not a solution for the millions of children who live in developing countries like Jordan, the Philippines, or Thailand, where the price is still too high.

At the lowest global prices, which aren’t accessible to most countries, it is now 68 times more expensive to vaccinate a child than in 2001, according to a 2015 MSF report, The Right Shot: Bringing Down Barriers to Affordable and Adapted Vaccines. The pneumonia vaccine accounts for almost half the price of the entire vaccination package for a child in the poorest countries. Also in 2015, all 193 countries at the World Health Assembly passed a landmark resolution demanding more affordable vaccines and increased transparency around vaccine prices.

Related News & Publications

Be part of MSF

Our supporters, donors, and fundraisers are a vital part of the MSF movement.

Find out how you can support MSF's lifesaving work.

Learn more